Oral Anticoagulant Discontinuation, Adherence Patterns, Hospitalizations and Costs in Non-Valvular Atrial Fibrillation (NVAF) Patients

• Status: Completed
• Trial end date: 2014-08-01
• Target enrollment: 0
• Participant gender: All

Summary

To describe the rate of discontinuation among Non-Valvular Atrial Fibrillation (NVAF) patients who were on warfarin and have switched to the Novel oral anticoagulants(NOACs).

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Anticoagulants; Apixaban; Dabigatran; Rivaroxaban; Warfarin

Criteria

Inclusion Criteria:

• Individuals with NVAF who were on warfarin and have switched to the NOACs (dabigatran, rivaroxaban and apixaban) within the study period January 01, 2013 through March 31, 2014

• Individuals ≥18 years old on the index date

• At least 1 year of baseline period with history of continuous warfarin use in the baseline period for at least 3 months immediately before the index date

• At least 1 diagnosis of AF in the 12 months prior to index date

• Continuous eligibility with medical and pharmacy benefits for at least 12 months before the index date through 1 month after the index date

Exclusion Criteria:

• Individuals with a diagnosis of valvular heart disease or cardiac surgery during the 12 months prior to index date